Avoro Capital Advisors Reduces $40M in MoonLake Immunotherapeutics ($MLTX)
Avoro Capital Advisors has completely exited its position in MoonLake Immunotherapeutics, selling all 2 million shares.
Key Points
- Avoro Capital Advisors sold all 2 million shares of MoonLake Immunotherapeutics, exiting its position entirely.
- MoonLake Immunotherapeutics, trading at $18.69, has a market cap of $1.38 billion and no meaningful P/E ratio as it's not profitable.
- Insiders have been selling shares recently, and analysts mostly maintain a buy rating with a mean target price of $27.62.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Avoro Capital Advisors has completely exited its position in MoonLake Immunotherapeutics (NasdaqCM: MLTX), selling all 2 million shares it held. This move was revealed in the firm's latest 13F filing with the SEC, which reflects holdings as of the end of the reporting period.
What Changed in Avoro Capital Advisors' MoonLake Immunotherapeutics Position
Avoro Capital Advisors completely sold its stake in MoonLake Immunotherapeutics, offloading 2 million shares. This marks a 100% reduction from its previous holdings, leaving it with no shares in the company.
Other Institutional Activity in MoonLake Immunotherapeutics
Several other institutional investors have been active in MoonLake Immunotherapeutics. BVF Inc/IL reduced its holdings by 3.75 million shares, ending with 16,001,284 shares valued at approximately $298.26 million. Deep Track Capital, LP, however, increased its position by 1,798,792 shares, bringing its total to 6,408,863 shares worth about $119.46 million. Cormorant Asset Management, LP added 125,000 shares, resulting in a total of 4,480,433 shares valued at $83.52 million. Janus Henderson Group PLC also boosted its stake by 1,355,640 shares, ending with 3,451,628 shares valued at $64.30 million.
MoonLake Immunotherapeutics Stock Up 32.8%
Shares of MoonLake Immunotherapeutics (NasdaqCM: MLTX) traded at around $18.69. The company has a market capitalization of approximately $1.38 billion. As it is not currently profitable, there is no meaningful P/E ratio. The stock's 52-week range has been between $5.95 and $62.75, with a 50-day moving average of $17.76 and a 200-day moving average of $19.56. MoonLake's beta is 1.036, indicating moderate volatility compared to the market.
$MLTX stock price
Daily closing prices, year to date. Not investment advice.
Insider Buying and Selling at MoonLake Immunotherapeutics
Recent insider activity at MoonLake Immunotherapeutics has shown several sales. Matthias Bodenstedt, the Chief Financial Officer, sold shares on multiple occasions under planned transactions, including 13,653 shares at $20.02 on May 11, 2026. CEO Jorge Santos da Silva also sold shares, including 51,873 shares at $18.23 on April 13, 2026, in an unplanned transaction.
Analysts Set New Price Targets
Analysts continue to show interest in MoonLake Immunotherapeutics. On May 12, 2026, Needham maintained a 'buy' rating with a target price of $30. HC Wainwright & Co. also maintained a 'buy' rating, setting a target price of $45 on May 11. Wolfe Research upgraded the stock to 'buy' with a $24 target on March 23. The consensus recommendation is a 'buy', with a mean target price of $27.62 based on 13 analyst opinions.
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing treatments for inflammatory skin and joint diseases. Its lead product, Sonelokimab, is a tri-specific Nanobody targeting IL-17A and IL-17F for conditions like hidradenitis suppurativa and psoriatic arthritis. Founded in 2021, the company is headquartered in Zug, Switzerland, and led by CEO Dr. Jorge Santos da Silva.
Bottom Line
Avoro Capital Advisors' complete exit from MoonLake Immunotherapeutics is a notable move among institutional investors. As a clinical-stage biotech firm, MoonLake is closely watched for its innovative therapies targeting inflammatory diseases. This 13F filing provides a snapshot of past holdings and may not reflect current positions, but it offers insight into institutional sentiment.
Get MoonLake Immunotherapeutics alerts
New 13F filings, insider trades, and analyst moves on $MLTX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.